| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Phosphatidylcholines, egg do not have a specific pharmacological target in the traditional sense but function as essential structural components of eukaryotic cell membranes. They serve as precursors for second messengers including diacylglycerol, phosphatidic acid, lysophosphatidic acid, and arachidonic acid, which are involved in various signaling pathways. As a surfactant within mucus, phosphatidylcholine forms a hydrophobic surface to inhibit bacterial penetrance. They are also strong bilayer-forming lipids.
|
|---|---|
| ln Vitro |
In vitro activities of Phosphatidylcholines, egg include their use in studying lipid bilayer mechanics, permeability regulation, and protein reconstitution in membrane-mimicking systems. They serve as model membranes for biophysical studies and as components of liposomal drug delivery systems. They can be metabolized to produce second messengers such as diacylglycerol and arachidonic acid. They function as surfactants within mucus to form hydrophobic surfaces that inhibit bacterial penetrance. Detailed quantitative activity data are not applicable as this is a structural lipid.
|
| ln Vivo |
In vivo activities of Phosphatidylcholines, egg are primarily related to their role as essential membrane components and precursors for signaling molecules. They are used to treat fat embolism. As major components of eukaryotic membranes, they are critical for maintaining cellular structure and function. They are also found at high levels in C. elegans lipid extracts. Their biological origin and high purity make them suitable for fundamental studies in biophysics, nanostructured lipid carriers, and model membrane development.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically applicable for Phosphatidylcholines, egg as they are structural lipids rather than enzyme inhibitors or receptor ligands. However, they can be used in binding studies involving lipid-protein interactions, where liposomes composed of egg phosphatidylcholine are used to study membrane protein incorporation and function. Surface pressure measurements using Langmuir-Blodgett troughs may be employed to study lipid monolayer properties. Standard protocols involve preparing liposomes by hydration of dried lipid films followed by extrusion through polycarbonate membranes.
|
| Cell Assay |
In vitro cell-based assays for Phosphatidylcholines, egg typically involve the use of liposomes for drug delivery studies or as model membranes for cell culture applications. Cells are treated with liposomal formulations containing egg phosphatidylcholine, and cellular uptake, cytotoxicity, or signaling pathway activation is evaluated. The lipid's role in membrane fluidity and permeability can be studied using fluorescent membrane probes. For protein reconstitution studies, membrane proteins are incorporated into liposomes and their activity is measured using biochemical or biophysical methods.
|
| Animal Protocol |
In vivo animal studies for Phosphatidylcholines, egg are typically conducted in the context of liposomal drug delivery or nutritional studies. Animals are administered liposomal formulations containing egg phosphatidylcholine via intravenous, oral, or intraperitoneal routes, and pharmacokinetics, biodistribution, and therapeutic efficacy are evaluated. For fat embolism treatment, animal models are used to assess the lipid's efficacy. Standard protocols include monitoring of body weight, organ weights, and histological examination of tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Phosphatidylcholines, egg are determined by their role as endogenous membrane components. As natural phospholipids, they are metabolized through normal lipid metabolic pathways. The compound has a CAS number of 97281-44-2 and appears as a white to off-white solid. Solubility includes ethanol: 50 mg/mL (need ultrasonic) and DMSO: 25 mg/mL (need ultrasonic). Storage recommendations include powder at -20°C for 3 years and in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Toxicity of Phosphatidylcholines, egg is generally considered low as they are naturally occurring phospholipids found in eukaryotic cell membranes. They are commonly used in pharmaceutical formulations and are generally recognized as safe. Standard safety precautions for handling research chemicals should be followed. The compound is designated for research use only. No significant toxicity data are reported in the available literature.
|
| References | |
| Additional Infomation |
1-Hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycerol-3-phosphate choline is a phosphatidylcholine 34:1, wherein the 1- and 2-acyl groups are designated as hexadecanoyl (palmitoyl) and 9Z-octadecenoyl (oleoyl), respectively. It is a mouse metabolite. It is a phosphatidylcholine 34:1, and also a 1-acyl-2-oleoyl-sn-glycerol-3-phosphate choline betaine. It is functionally related to hexadecanoic acid and oleic acid. 1-Palmyl-2-oleoyl-sn-glycerol-3-phosphate choline has been reported in Streptomyces roseum, Drosophila melanogaster, and other organisms with relevant data. PC (16:0/18:1(9Z)) is a metabolite found or produced in Saccharomyces cerevisiae.
Phosphatidylcholines, egg (CAS: 97281-44-2) are naturally sourced phospholipids extracted from egg yolk, composed primarily of unsaturated fatty acids. They are essential components of eukaryotic membranes and precursors of second messengers. They support studies on lipid bilayer mechanics, permeability regulation, and protein reconstitution. They are used in biophysics, nanostructured lipid carriers, and model membrane development. They also function as surfactants within mucus to inhibit bacterial penetrance and are used to treat fat embolism. |
| Molecular Formula |
C42H82NO8P
|
|---|---|
| Molecular Weight |
760.07618
|
| Exact Mass |
759.578
|
| CAS # |
97281-44-2
|
| PubChem CID |
5497103
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
41
|
| Heavy Atom Count |
52
|
| Complexity |
899
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCC/C=C\\CCCCCCCC
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol :~50 mg/mL (with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one),clear solution.
For example, if 1 mL of working solution is to be prepared,you can add 100 μL of 25.0 mg/mL clear EtOH stock solution and add it to 400 μL PEG300 and mix well. Then add 50 μL Tween-80 to the above system and mix well. Then continue to add 450 μL of physiological saline to make up to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3157 mL | 6.5783 mL | 13.1565 mL | |
| 5 mM | 0.2631 mL | 1.3157 mL | 2.6313 mL | |
| 10 mM | 0.1316 mL | 0.6578 mL | 1.3157 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
